Risk stratification in multiple myeloma Published 2022-05-12 Download video MP4 360p Download video MP4 720p Recommendations 04:34 What Is the Future for CAR-T in Multiple Myeloma? 01:56 Long noncoding RNAs represent potential therapeutic targets in multiple myeloma 02:26 Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma 01:13 Exciting updates in CLL: advancing treatment for patients with double-refractory disease 02:18 Efficacy of subsequent therapies for CLL patients treated in the MURANO trial 02:48 MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma 01:21 The REMNANT study: will treating patients at MRD relapse improve survival outcomes? 01:29 Replacing dexamethasone in transplant-ineligible multiple myeloma: the REST study 04:57 Analysis of clinical outcomes & HRU in patients with AML treated with venetoclax vs other therapies 01:43 Ide-cel therapy for multiple myeloma with renal impairment 08:11 Improvements over time in elderly patients with AML treated with alloSCT: an EBMT Registry study 01:49 The management of Richter's transformation: current approaches and future outlooks 01:54 Final results of the GIMEMA LAL2317 trial: sequential chemotherapy + blinatumomab for Ph- B-ALL 06:43 Should JAK2 VAF testing be implemented as routine in risk assessment and disease monitoring in MPN? 03:09 An overview of the toxicities associated with immunotherapy in multiple myeloma 00:59 The importance of the EBMT-EHA European CAR T-cell meeting 2024 01:29 Managing toxicities associated with immunotherapy in multiple myeloma 02:13 SATISFY: mitapivat in patients with erythrocyte membranopathies 03:53 Mutational Burden in Patients with Treatment-Naïve CLL 01:55 Safety and efficacy of NXC-201, an anti-BCMA CAR-T, in R/R AL amyloidosis Similar videos 02:07 Redefining risk stratification in multiple myeloma 05:04 The PANGEA model: improving risk stratification in multiple myeloma 01:57 Using molecular abnormalities for risk stratification in multiple myeloma at the time of diagnosis 04:51 Risk stratification & treatment of multiple myeloma precursor conditions 05:16 Updated risk stratification model for smoldering multiple myeloma 17:48 MCRT Phoenix 2017: MM Diagnosis and Risk Stratification by Shaji Kumar, MD 01:51 Key features of the PANGEA model: improving risk stratification in myeloma 05:45 Risk Stratification for Myeloma 29:55 MCRT Baltimore 2018: Bone Disease and Multiple Myeloma Risk Stratification by David Vesole, MD 00:24 Risk Stratification for MGUS | Dr. S. Vincent Rajkumar | Oncology Brothers 07:44 Smoldering Myeloma: Treatment and Risk Stratification 01:25 The importance of risk stratification and redefining high-risk in myeloma 01:28 Risk stratification models for smoldering myeloma 01:47 Risk stratification of MGUS 02:18 Smouldering myeloma: detection, risk stratification and defining a new standard of care 06:50 Case 2: Molecular Risk Stratification in Myeloma 29:18 Risk Stratification of Plasma Cell Disorders 02:37 Study on Risk Stratification in Smoldering Myeloma Patients | Malin Hultcrantz, MD, PhD | IMS 2023 More results